MADRIGAL PHARMACEUTICALS, INC. — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 38/100
What the filing says
Madrigal Pharmaceuticals announced August 12, 2026 the appointment of John C. Reed, M.D., Ph.D. to its Board of Directors. Reed is EVP of Innovative Medicine R&D at Johnson & Johnson and J&J Executive Committee member, with prior executive roles at Sanofi, Roche, and Sanford-Burnham. He brings 900+ publications, 130+ patents, and deep expertise in drug discovery and global R&D strategy to support Madrigal's MASH pipeline and Rezdiffra commercialization.
Why this rating
Board appointment is positive for credibility and R&D guidance but routine governance. No financial impact, no deal, no operational change. Modest for $5.6B company.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.